BC PharmaCare is looking for your input on tocilizumab (Actemra™) for the treatment of giant cell arteritis
Tocilizumab (Actemra®) for giant cell arteritis (GCA) is now being considered for coverage under the British Columbia Ministry of Health’s PharmaCare program. By filling out a questionnaire on a website called Your Voice, you can provide feedback about tocilizumab for the treatment of GCA.
You can give input if you are a B.C. resident and have giant cell arteritis, a caregiver to someone with giant cell arteritis, or if your group represents people who live with giant cell arteritis.
If you would like our help in providing your input, you can email us your input at email@example.com or call us at 604-974-1366. We can send it as a patient organization on your behalf. Please provide your input to us by Monday, February 19 so that we may submit the questionnaire in time for the deadline.
The submission deadline is midnight on February 21, 2018. Patients and caregivers may give their input directly through the links below.
Please click here to let BC PharmaCare hear Your Voice. Or, go to the following links:
- To view the information sheet for tocilizumab for giant cell arteritis: click here
- For the Patient Questionnaire: click here
- For the Caregiver Questionnaire: click here
- For the Patient Group Questionnaire: click here (Patient groups are required to register their name with the Ministry of Health before making their submission.)